Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | GMNN | O75496 | 1/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | APEX1 | P27695 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4473859 | 1.00 | MAPT (0.47) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4490484 | 0.93 | MAPT (0.53) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4490574 | 0.93 | MAPT (0.53) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4500095 | 0.91 | MAPT (0.51) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4500098 | 0.91 | MAPT (0.51) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4194175 | 0.81 | HCAR2 (0.50) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL4194178 | 0.81 | HCAR2 (0.50) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL1879178 | 0.78 | HCAR2 (0.56) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL3594049 | 0.78 | HCAR2 (0.56) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL23666175 | 0.76 | HCAR2 (0.54) | MAPTHCAR2ALDH1A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2112134-B1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD (IL) | 2013-10-30 | — | — | EP | disclosed |
| EP-2112134-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | Syndromex Ltd. (IL) | 2009-10-28 | — | — | EP | disclosed |
| US-6800772-B2 | FOR TREATING HYPERLIPIDEMIA, OBESITY AND IMPAIRED GLUCOSE TOLERANCE/NONINSULIN DEPENDENT DIABETES MELLITUS WITHOUT AFFECTING ENERGY METABOLISM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-10-05 | — | — | US | disclosed |
| US-20040132818-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD. (IL) | 2004-07-08 | — | — | US | disclosed |
| US-20020049345-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | SYNDROMEX LTD. (IL) | 2002-04-25 | — | — | US | disclosed |
| US-6284903-B1 | TREATING HYPERLIPIDEMIA, OBESITY AND IMPAIRED GLUCOSE TOLERANCE/NONINSULIN DEPENDENT DIABETES MELLITUS WITHOUT ADVERSELY AFFECTING ENERGY METABOLISM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2001-09-04 | — | — | US | disclosed |
| EP-0988274-A4 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RES DEV CO (IL) | 2000-10-18 | — | — | EP | disclosed |
| EP-0988274-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998030530-A1 | CARBOXYLIC ACIDS AND DERIVATIVES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | YISSUM RESEARCH DEVELOPMENT CO. OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 1998-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132818-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | CYP2F1, QPCT, CBR3 | MAPT 3942/4885HCAR2 91/4885ALDH1A1 209/4885 |
| US-20020049345-A1 | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them | CYP2F1, QPCT, CYP2D6 | MAPT 4005/4885HCAR2 95/4885ALDH1A1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.